About NeuMoDx
NeuMoDx is a company based in Ann Arbor (United States) founded in 2012 was acquired by Qiagen in September 2020. NeuMoDx has raised $66.04 million across 5 funding rounds from investors including Qiagen, Baird Capital and Venture Investors. The company has 125 employees as of December 31, 2022. NeuMoDx operates in a competitive market with competitors including DermTech, GenMark Diagnostics, Biocartis, Biomeme and Molbio Diagnostics, among others.
- Headquarter Ann Arbor, United States
- Employees 125 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Neumodx Molecular, Inc
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of NeuMoDx
Unlock access to complete
Unlock access to complete
Software Development Team
67 people
Leadership Team
56 people
Sales and Marketing
55 people
Senior Team
47 people
Human Resources and Administration
29 people
Operations Team
17 people
Product Management Team
16 people
Field Team
14 people
Unlock access to complete
Funding Insights of NeuMoDx
NeuMoDx has successfully raised a total of $66.04M across 5 strategic funding rounds. The most recent funding activity was a Series B round of $20.04 million completed in April 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in NeuMoDx
NeuMoDx has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Qiagen, Baird Capital and Venture Investors.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Global private equity and venture capital investments in B2B Tech & Services companies.
|
Locked | Locked | Locked | |
|
Multiple sectors focused seed & early stage VC firm investing in the US, Europe & Asia
|
Locked | Locked | Locked | |
|
Healthcare venture capital investments are made by Arboretum Ventures.
|
Locked | Locked | Locked |
Investor details for NeuMoDx
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by NeuMoDx
Investment portfolio details for NeuMoDx
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - NeuMoDx
Detailed financials for NeuMoDx
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Neumodx Comparisons
Peer comparison for NeuMoDx
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of NeuMoDx
NeuMoDx operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as DermTech, GenMark Diagnostics, Biocartis, Biomeme and Molbio Diagnostics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Adhesive patch biopsies for skin cancer detection are provided.
|
|
| Locked | Locked | Locked |
Instruments and test panels for multiplexed molecular diagnostics are provided.
|
|
| Locked | Locked | Locked |
Molecular assays for disease detection are developed using proprietary technology.
|
|
| Locked | Locked | Locked |
Smartphone-based DNA detection platform is developed for diagnostics.
|
|
| Locked | Locked | Locked |
Point-of-care molecular platforms for infectious disease detection are developed.
|
Detailed competitors of NeuMoDx
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Neumodx
Complete news archive for NeuMoDx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about NeuMoDx
NeuMoDx was founded in 2012.
NeuMoDx is headquartered in Ann Arbor, United States. It is registered at Ann Arbor, Michigan, United States.
NeuMoDx is a funded company, having raised a total of $66.04M across 5 funding rounds to date.
As of Dec 31, 2022, the latest employee count at NeuMoDx is 125.
NeuMoDx was founded in 2012 and is located in Ann Arbor, United States. A patent-pending platform for molecular testing is developed, focusing on the diagnostics sector. Magnetic particle affinity capture and real-time PCR chemistry are combined in a multi-sample microfluidic cartridge. The lead product, NeuMoDx 500, is utilized as a fully automated, random-access in vitro diagnostic system for RNA and DNA-based assays.
NeuMoDx's top competitors include DermTech, GenMark Diagnostics and Biocartis.
NeuMoDx has 6 investors. Key investors include Qiagen, Baird Capital, Venture Investors, Arboretum Ventures, and Pfizer Venture Investments.